In Brief: FDA's Oncologic Drugs Advisory Committee

FDA's Oncologic Drugs Advisory Committee: Will meet Dec. 14 to discuss Bryant Corp.'s Luzenac sterile aerosol talc (NDA 20-587) for treatment of malignant pleural effusion and NeoRx' monoclonal antibody OncoTrac (PLA 94-0308) for small-cell lung cancer. Boehringer Ingelheim retains exclusive marketing rights to OncoTrac outside North America, and NeoRx is in a marketing alliance with DuPont Merck for the North American rights to the product. The advisory committee also will discuss FDA oncology initiatives. The meeting will take place at the Bethesda Holiday Inn, Bethesda, Md., beginning at 8 a.m...